Claims for Patent: 7,316,816

Summary for Patent: 7,316,816

Title:	Temperature and pH sensitive copolymers
Abstract:	The invention is directed to a copolymer comprising at least three types of monomeric units, said three types of monomeric units comprising: a temperature-sensitive unit, a hydrophilic unit, and a hydrophobic unit comprising at least one pH-sensitive moiety; wherein said hydrophobic monomeric unit is derived from a copolymerisable unsaturated fatty acid.
Inventor(s):	Yang; Yi-Yan (Singapore, SG), Soppimath; Kumaresh (Singapore, SG)
Assignee:	Agency for Science Technology and Research (Singapore, SG)
Application Number:	10/865,681
Patent Claims:	1. An amphiphilic copolymer comprising at least three types of monomeric units, said three types of monomeric units comprising: a temperature-sensitive monomeric unit, a hydrophilic monomeric unit, wherein the hydrophilic monomeric unit has one or more polar functionalities, and a hydrophobic monomeric unit comprising at least one pH-sensitive moiety; wherein said hydrophobic monomeric unit is derived from a copolymerisable unsaturated fatty acid, wherein said unsaturated fatty acid imparts hydrophobic character to the copolymer; wherein the copolymer has a lower critical solution temperature (LCST) dependent on environmental pH; wherein said lower critical solution temperature (LCST) decreases as pH decreases; wherein the fatty acid comprises 5 to 50 or more main chain carbon atoms; and wherein the fatty acid comprises at least 2 carbon-carbon double bonds (polyunsaturated). 2. The copolymer of claim 1, wherein the fatty acid is selected from the group consisting of(E,E)-9,12-Octadecadienoic Acid, (Z,Z)-9,12-Octadecadienoic Acid, (E,E)-9,11-Octadecadienoic Acid, (Z,Z,Z)-9,12,15-Octadecatrienoic Acid, (Z,Z,Z)-6,9,12-Octadecatrienoic Acid, (Z,Z,Z,Z)-6,9,12,15-Octadecatetraenoic Acid, (Z,Z,)-11,14-Ecosadienoic Acid, (Z,Z,Z)-5,8,11-Eicosatrienoic Acid, (Z,Z,Z)-11,14,1 7-Eicosatrienoic Acid, (Z,Z,Z)-8,11,14-Eicosatrienoic Acid, (Z,Z,Z,Z)-8,11,14,17-Eicosatetraenoic Acid, (Z,Z,Z,Z)-5,8, 11,14-Eicosatetraenoic Acid, (Z,Z,Z,Z,Z)-5,8,11,14,17-Eicosapentaenoic Acid, (Z,Z)-13,16-Docosadienoic Acid, (Z,Z,Z)-13,16,19-Docosatrienoic Acid, (Z,Z,Z,Z)-7,10-13-16-Ocosatetraenoic Acid, (Z,Z,Z,Z,Z)-4,7,10,13,1 6-Docosapentaenoic Acid, (Z,Z,Z,Z,Z)-7,10,13,16,19-Docosapentaenoic Acid, (Z,Z,Z,Z,Z,Z)-4,7,10,13,16,19-Docosahexaenoic Acid, and (Z,Z,Z,Z,Z,Z)-6,9,12,15,18,21-Tetracosahexaenoic Acid. 3. The copolymer of claim 1, wherein the temperature sensitive monomeric unit is derived from the group consisting of N-acroylpiperadine, N-t-butylacrylamide, N-piperidyl-methacrylamide and N-isopropylacrylamide. 4. The copolymer of claim 1, wherein the hydrophilic monomeric unit is derived from the group consisting of acrylic acid, acrylamide, acrylate, and substituted derivatives thereof. 5. The copolymer of claim 4, wherein the acrylamide is selected from the group consisting of acrylamide (AAm), N,N'-dimethylacrylamide (DMAAm), and N-(hydroxymethyl)acrylamide. 6. The copolymer of claim 1, further comprising a terminal group comprising at least one moiety selected from the group consisting of a terminating moiety, a ligand, a drug, a tag, a radioimmunoconjugate and a spacer. 7. The copolymer of claim 6, wherein the terminating moiety comprises a functional group selected from the group consisting of a hydroxyl group, a carboxyl group and an amino group. 8. The copolymer of claim 7, wherein the terminating moiety is introduced by chain transfer agents or group transfer agents. 9. The copolymer of claim 7, wherein the terminating moiety is introduced by living polymerisation methods. 10. The copolymer of claim 7, wherein the terminating moiety is part of the monomeric unit of the polymer. 11. The copolymer of claim 8, wherein the chain transfer agent is selected from the group consisting of chloroform, carbon tetrachloride, alkyl-mercaptans, aminoethanethiol, mercapto-propionic acid, mercapto-succinic acid, thioglycolic acid, mercaptoethanol and secondary alcohols thereof, alkyl halides, and salts of phosphorus acids with an oxidation number less than 5. 12. The copolymer of claim 11, wherein the aikyl-mercaptans are selected from the group consisting of octanethiol, decanethiol, n-dodecanethiol or t-dodecanethiol. 13. The copolymer of claim 6, wherein said ligand is attached to the functional group of the terminating moiety directly. 14. The copolymer of claim 6, wherein said ligand is attached to the terminating moiety by a spacer. 15. The copolymer of claim 14, wherein said spacer comprises more than 10 main chain atoms. 16. The copolymer of claim 15, wherein said ligand is selected from the group consisting of small targeting molecules, proteins, peptides and carbon hydrates. 17. The copolymer of claim 15, wherein the spacer comprises poly(ethylene glycol) and poly(propylene glycol). 18. The copolymer of claim 1, wherein the copolymer is a random copolymer. 19. A temperature and pH sensitive composition comprising: a therapeutic agent, and the copolymer of claim 1 and wherein the fatty acid comprises 5 or more main chain carbon atoms. 20. The composition of claim 19, wherein the therapeutic agent is selected from the group consisting of an anticancer drug, an anti-inflammatory drug and a drug to treat neurological disorders. 21. The composition of claim 20, wherein the anticancer drug is selected from the group consisting of doxorubicin, anastrozole, exemestane, cyclophosphamide, epirubicin, toremifene, letrozole, trastuzumab, megestrol, nolvadex, paclitaxel, docetaxel, capecitabine, goserelin acetate, hydroxy urea, erythromycin, cyclosporin and cisplatin. 22. The composition of claim 19, wherein the molecular weight of the copolymer is less than 40,000 as determined by GPC. 23. The composition of claim 19, wherein the lower critical solution temperature of the copolymer is lower than 37.degree. C. at a pH of less than 7.2. 24. The composition of claim 19, wherein the lower critical solution temperature of the conolymer is higher than 37.degree. C. at a pH of 7.4 (normal physiological pH). 25. The composition of claim 19, wherein the mole ratio of temperature sensitive monomeric units to hydrophilic monomeric units to the hydrophobic monomeric units comprising at least one pH-sensitive moiety present in the copolymer is about 3.75 : 1.25 : 0.5. 26. A method of providing a selected therapeutic agent to an animal or human, comprising administering to said animal or human a temperature and pH-sensitive composition comprising: a therapeutic agent, and the copolymer of claim 1. wherein said copolymer is arranged into at least one nanoparticle comprising a hydrophobic core and a hydrophilic shell; and wherein said therapeutic agent is contained within said hydrophobic core. 27. The method of claim 26, wherein the composition is delivered orally. 28. The method of claim 26, wherein the composition is delivered locally. 29. The method of claim 26, wherein the composition is delivered intravenously. 30. The method of claim 26, wherein the composition is delivered tropically. 31. The method of claim 26, wherein the composition is delivered parenterally. 32. The method of claim 26, wherein the composition is delivered through inhalation. 33. The method of claim 26, wherein the composition is delivered through an ocular route. 34. An amphiphilic copolymer comprising at least three types of monomeric units, said three types of monomeric units comprising: a temperature-sensitive monomeric unit, a hydrophilic monomeric unit, wherein the hydrophilic monomeric unit has one or more polar functionalities, and a hydrophobic monomeric unit comprising at least one pH-sensitive moiety; wherein said hydrophobic monomeric unit is derived from a copolymerisable unsaturated fatty acid, wherein said unsaturated fatty acid imparts hydrophobic character to the copolymer; wherein the copolvmer has a lower critical solution temperature (LCST) dependent on environmental pH; wherein said lower critical solution temperature (LCST) decreases as pH decreases; and wherein the copolymer is a block copolymer. 35. The copolymer of claim 34, wherein the fatty acid comprises 5 to 50 main chain carbon atoms. 36. The copolymer of claim 35, wherein the fatty acid comprises at least 2 carbon-carbon double bonds (polyunsaturated). 37. The copolymer of claim 36, wherein the fatty acid is selected from the group consisting of (E,E)-9,12-Octadecadienoic Acid, (Z,Z)-9,12-Octadecadienoic Acid, (E,E)-9,11-Octadecadienoic Acid, (Z,Z,Z)-9,12,15-Octadecatrienoic Acid, (Z,Z,Z)-6,9,12-Octadecatrienoic Acid, (Z,Z,Z,Z)-6,9,12,1 5-Octadecatetraenoic Acid, (Z,Z,)-11,14-Ecosadienoic Acid, (Z,Z,Z)-5,8,11-Eicosatrienoic Acid, (Z,Z,Z)-11,14,17-Eicosatrienoic Acid, (Z,Z,Z)-8,11,14-Eicosatrienoic Acid, (Z,Z,Z,Z)-8,11,14,17-Eicosatetraenoic Acid, (Z,Z,Z,Z)-5,8,11,14-Eicosatetraenoic Acid, (Z,Z,Z,Z,Z)-5,8,11,14,17-Eicosapentaenoic Acid, (Z,Z)-13,16-Docosadienoic Acid, (Z,Z,Z)-13,16,19-Docosatrienoic Acid, (Z,Z,Z,Z)-7,10-13-16-Ocasatetraenoic Acid, (Z,Z,Z,Z,Z)-4,7,10,13,1 6-Docosapentaenoic Acid, (Z,Z,Z,Z,Z)-7,10,13,16,19-Docosapentaenoic Acid, (Z,Z,Z,Z,Z,Z)-4,7,10,13,16,19-Docosahexaenoic Acid, and (Z,Z,Z,Z,Z,Z)-6,9,12,15,18,21-Tetracosahexaenoic Acid. 38. The copolymer of claim 34, wherein the temperature sensitive monomeric unit is derived from the group consisting of N-acroylpiperadine, N-t-butylacrylamide, N-piperidyl-methacrylamide and N-isopropylacrylamide. 39. The copolymer of claim 34, wherein the hydrophilic monomeric unit is derived from the group consisting of acrylic acid, acrylamide, acrylate, and substituted derivatives thereof. 40. The copolymer of claim 34, further comprising a terminal group comprising at least one moiety selected from the group consisting of a terminating moiety, a ligand, a drug, a tag, a radioimmunoconjugate and a spacer.

Details for Patent 7,316,816

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-02-26
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2039-02-26